New Long-Read Genetic Test Enables Faster and More Comprehensive Diagnosis of Rare Diseases
November 18, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Nasorest
Synonyms :
acrivastine
Class :
Antihistamine, Antiallergic
Brand Name :
Nasorest
Synonyms :
acrivastine
Class :
Antihistamine, Antiallergic
Dosage Forms & Strengths
Capsule
8 mg
Take a dose of 8 mg orally as required up to three times a day
Dosage Forms & Strengths
Capsule
8 mg
For >12years old:
Take a dose of 8 mg orally as required up to three times a day
Refer to adult dosing
may decrease the excretion rate when combined with each other
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
CNS Depressants: they may increase the CNS depressant effect of antihistamines
It may enhance sedation when combined with tramadol
It may enhance sedation when combined with codeine
may increase the risk or severity of QTc prolongation when combined
pitolisant: they may decrease the therapeutic effect of antihistamines
It may enhance sedation when combined with oxycodone
revefenacin: they may decrease the therapeutic effect of antihistamines
QTc prolongation can be seen when acrivastine is used in combination with cinoxacin
acrivastine can increase the risk or severity of QTC prolongation when used in combination with vernakalant
the anticoagulant effects of acrivastine may be increased with benzylpenicilloyl polylysine
It may enhance sedation when combined with phenobarbital
It may enhance sedation when combined with perphenazine
It may enhance the sedation effect when combined with lumateperone
it may enhance the risk of QTc prolongation when combined with amifampridine
It may enhance the sedation when combined with tasimelteon
ajmaline enhances the risk of QTc prolongation when combined with acrivastine
it may diminish the excretion rate when combined with gadofosveset, resulting in an enhanced serum level
aminophenazone has the potential to reduce the rate of excretion of acrivastine leading to an elevation in its serum concentration
meticrane has the potential to enhance the rate of excretion of acrivastine; this can potentially lead to decreased levels of serum, possibly diminishing its effectiveness
levobupivacaine has the potential to lower the rate of excretion of acrivastine, leading to a possible elevation in serum levels
tinidazole has the potential to reduce the rate of excretion of acrivastine, potentially leading to an elevation in level of serum
When ponesimod is used together with acrivastine, this leads to enhanced risk or seriousness of bradycardia
When acrivastine is used together with adenosine, this leads tob enhanced risk or seriousness of QTc prolongation
When acrivastine is used together with givinostat, this leads to enhanced risk or severity of Qtc prolongation
acrivastine leads to a reduction in the rate of excretion of eucalyptus oil which leads to increased level of serum
cefpirome leads to a reduction in the rate of excretion of acrivastine which leads to increased level of serum
acrivastine leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
acrivastine leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
ioxilan may lower the excretion rate of acrivastine, potentially resulting in a higher serum level
phylloquinone may lower the excretion rate of acrivastine, potentially leading to higher serum levels
muzolimine may raise the excretion rate of acrivastine, potentially resulting in a lower serum level and a potential decrease in efficacy
acrivastine excretion rate may be decreased by mycophenolic acid, potentially leading to higher serum levels
acrivastine may the excretion rate of n-acetyl tyrosine, potentially resulting in elevated serum levels
sulbactam may lower the excretion rate of acrivastine, which could result in a serum level rise
acrivastine: it may increase the risk or severity of CNS depression
acrivastine: it may increase the risk or severity of CNS depression
acrivastine: it may increase the risk or severity of CNS depression
acrivastine: it may increase the risk or severity of CNS depression
acrivastine: it may increase the risk or severity of CNS depression
the issue of QTc prolongation can be heightened when prenylamine is combined with acrivastine
the risk or intensity of QTc prolongation can be heightened when ibandronate is combined with acrivastine
acrivastine: it may decrease the excretion rate of amikacin
acrivastine: it may increase the risk or severity of QTc prolongation agents
acrivastine: it may increase the risk or severity of QTc prolongation agents
acrivastine: it may increase the risk or severity of QTc prolongation agents
acrivastine: it may increase the risk or severity of QTc prolongation agents
acrivastine: it may increase the risk or severity of QTc prolongation agents
may decrease the tiopronin excretion rate
may decrease the therapeutic effect of carbinoxamine
may decrease the therapeutic effect of hyaluronidase
may decrease the therapeutic effect of betahistine
atomoxetine: they may increase the stimulatory effect of antihistamines
glucagon: they may decrease the therapeutic effect of antihistamines
adrenochrome monosemicarbazoneÂ
The efficacy of adrenochrome mono semicarbazone is decreased with antihistaminics when used in combination
the excretory rate of acrivastine may be reduced, resulting in increased levels of serum, when combined with kebuzone
the rate of excretion of inositol may be reduced
the risk of QTc prolongation may be increased
an increase in sedation can be seen if coadministered
the rate of excretion of acrivastine may be reduced
the rate of excretion of acrivastine may be reduced
the therapeutic effect of protokylol may be increased
the therapeutic effects of racepinephrine may be increased
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
may diminish the rate of excretion which results in higher serum level
choline magnesium trisalicylateÂ
choline magnesium trisalicylate may diminish the excretion rate of acrivastine, potentially resulting in a higher serum level
amiloride: it may increase the excretion rate of acrivastine
aminophenazone: it may decrease the excretion rate of acrivastine
Actions and Spectrum
acrivastine is a second-generation H1 histamine receptor antagonist. It works by blocking the action of histamine, a natural substance in the body that is released during allergic reactions.
Histamine is responsible for the symptoms of allergic reactions, and by blocking histamine receptors, it helps alleviate these symptoms.
Frequency not defined
Dry mouth
Dizziness
Drowsiness
Black Box Warning
None
Contraindication/Caution:
Contraindication:
Caution:
The use of acrivastine during pregnancy or while breastfeeding should monitor with caution.
Pregnancy consideration:
Pregnancy category: B
Lactation: Excretion into human milk is unknown
Pregnancy Categories:     
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology
acrivastine’s mode of action is to selectively antagonize H1 receptors, which are found in various tissues, including the respiratory and vascular systems.
H1 receptors are activated by histamine, leading to symptoms like sneezing, itching, runny nose, and watery eyes during allergic reactions.
Pharmacodynamics
acrivastine competes with histamine for binding to H1 receptors, effectively blocking histamine’s actions. It reduces or prevents the allergic symptoms caused by histamine.
Pharmacokinetics
Absorption
acrivastine is rapidly absorbed from the gastrointestinal tract after oral administration.
Distribution
acrivastine is widely distributed throughout the body.
Metabolism
acrivastine undergoes minimal metabolism in the liver.
Elimination and excretion
acrivastine is excreted through the renal route.
Administration
acrivastine is available in the form of capsules for oral intake.
Patient information leaflet
Generic Name: acrivastine
Why do we use acrivastine?
acrivastine is used in the treatment of allergic conditions and allergic conjunctivitis.
acrivastine is frequently used to treat the symptoms of allergic rhinitis also known as hay fever.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
